After leaving X as CEO, Linda Yaccarino's next role will be another CEO of EMED Population Health, an AI startup that builds a technology platform for patients using GLP-1.
Yaccarino was a longtime advertising executive at NBCuniversal, but was forced to join X as CEO for two years. Despite her and Elon Musk's sharing approach to minimizing moderation in shared content, it had a positive impact on the social network-related ad revenue model.
Jaccarino has no experience in health technology, but in a press release she said she sought “an undeniable ability to negotiate a new partnership.”
EMED previously had instructed users on the process of properly managing these tests and produced a high-tech platform designed for use in home-based Covid-19 rapid antigen testing. Currently, EMED is focusing on GLP-1, a class of drugs like Ozempic that can be used for both weight management and treatment of type 2 diabetes.
“To be a leader in today's healthcare market, companies need to have fearless tenacity that allows them to not only grow, but also to be brave enough to advance and redefine the entire industry,” Jaccarino said in a press release. “We are such a tenacious leader and are extremely well positioned as working towards our ultimate goal of improving global healthcare outcomes through groundbreaking services and platforms.”